

# Registry Study to Observe Long-term Safety of Vamorolone (AGAM-REE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

NCT06564974

---

Status	RECRUITING
Sponsor	Catalyst Pharmaceuticals, Inc.
Enrollment	250 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Patient or parent/legal guardian is willing and able to provide written informed consent once the nature of the registry has been explained and prior to the start of any registry-related procedures.
- Patient and/or parent/guardian are willing and able to complete QoL questionnaires.
- Male patients at least 2 years old.
- Confirmed diagnosis of DMD (via genetic testing or muscle biopsy with absent dystrophin staining to anti- dystrophin antibodies 3, 1, or 2, or dystrophin immunohistochemistry or western blot).
- Patient has a current, active prescription for, or is on, AGAMREE®.

### Exclusion (1)

- \. Any contraindication to AGAMREE® or medical condition, which, in the opinion of the Investigator, would affect registry participation, performance, or interpretation of registry assessments.

## Locations (27 total)

---

Phoenix Children's Hospital, Phoenix, Arizona, United States  
Arkansas Childrens Hospital, Little Rock, Arkansas, United States  
Children's Hospital Los Angeles, Los Angeles, California, United States  
... and 24 more locations